INFINIUM (INFINIUM) fundamentals
INFINIUM is a listed company, part of the Chemicals sector, listed on the NSE as INFINIUM (ISIN INE0MRE01011). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What INFINIUM does
Infinium Pharmachem Limited is an India-based company. The Company is engaged in the development, manufacture, and export of a spectrum of the Iodine Derivatives that are used in pharmaceutical, chemical, biotech and allied industries across the globe. Its portfolio includes approximately 200+ Iodine Derivatives and seven Active Pharmaceutical Ingredients (APIs). It manufactures and supplies a range of Iodine-based APIs, but on an Order-to-Made basis only. It offers Bulk Actives, intermediates and services for custom synthesis. It also provides contract research and manufacturing services to pharmaceutical and biotech companies for their diverse requirements of Iodine-based APIs and intermediates to reduce their research time and project cost. It manufactures iodine derivatives for various industries, including pharmaceutical, chemical, nutraceutical, cosmetics, sanitation, agrochemical, electronics, nylon production, and other industries for their range of industrial applications.
Valuation and market data
| Last close | ₹266.20 |
|---|---|
| Market capitalisation | ₹373 crore |
| Enterprise value | ₹348 crore |
| P/E (TTM) | 3.30 |
| Price to book | 2.99 |
| Price to sales (TTM) | 0.74 |
| Book value per share | ₹89.14 |
| Dividend yield | 0.00% |
| Sector | Chemicals |
| Industry | — |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹158 crore | ₹14 crore | ₹10 crore | 0.00 |
| Mar 2025 | ₹139 crore | ₹12 crore | ₹8 crore | 5.82 |
| Mar 2024 | ₹124 crore | ₹15 crore | ₹11 crore | 7.97 |
| Mar 2023 | ₹103 crore | ₹12 crore | ₹9 crore | 18.00 |
| Mar 2022 | ₹75 crore | ₹7 crore | ₹6 crore | 54.13 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Mar 2026:
| Promoters | 64.9% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.2% |
| Retail and others | 34.9% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.